Page 6,693«..1020..6,6926,6936,6946,695..6,7006,710..»

Law Rewards Drug Companies for Developing Cancer Drugs for Kids

Posted: Published on July 10th, 2012

Jul 9, 2012 9:38pm Image credit: Nancy Goodman/Kids v. Cancer President Obama signed a bill today that will provide incentives to drug companies to research and develop drugs for rare diseases. The Creating Hope Act grants pharmaceutical companies that create drugs for diseases like childhood cancers a voucher giving speedier review of any other drug they submit for approval. The Oval Office signature was a hard-fought victory for children like Mollie Ward, 11, who survived a rare form of pancreatic cancer thanks to an experimental drug, and for other families who have fought childhood cancers. Nancy Goodman, founder of Kids v. Cancer, which is devoted to pediatric cancer research, lost her son Jacob Froman, 10, to a rare form of brain cancer nearly four years ago. Hed been diagnosed at the age of 8. She was instrumental in getting the bill passed. She and others said that drug companies had little financial incentive to develop new treatments because childhood cancers are so rare. The reason I started working on the Creating Hope Act was that I found very early on that there are just very few drugs to treat kids with cancer, she told ABC News. We created a big, … Continue reading →

Posted in Drugs | Comments Off on Law Rewards Drug Companies for Developing Cancer Drugs for Kids

Pharmacy robbed at gunpoint

Posted: Published on July 10th, 2012

Two armed men robbed a northeast Indiana pharmacy before dawn Monday, forcing two employees onto the floor and the other to open the safe before grabbing medications. The Warsaw Police Department is investigating the robbery that happened at the CVS Pharmacy, 100 N. Detroit St., about 4:10 a.m. In a written statement, the department said the men were 20-30 years old and white. One was wearing a full-face red plastic Spider-Man mask with red tightening straps and surgical gloves. The other was wearing a tan safari-type hat or possible straw hat, a blue bandanna covering his face, sunglasses and surgical-type gloves. The employees watched the robbers head to the front door, but they could not get out, so they left out a side emergency exit. Warsaw police brought in a police dog to track the robbers north along the train tracks, but the trail ended near the parking lot south of the Salvation Army on Arthur Street, the statement said. Anyone with information about the robbery is asked to call the Warsaw Police Investigations Division at 574-372-9535 or call Crime Stoppers at 800-342-7867. Continued here: Pharmacy robbed at gunpoint … Continue reading →

Posted in Pharmacy | Comments Off on Pharmacy robbed at gunpoint

TiGenix : enrolment first patients in pivotal Phase III trial with lead product Cx601

Posted: Published on July 10th, 2012

Regulated information July 10, 2012 TiGenix enrolls first patients in pivotal Phase III trial with lead product Cx601 in perianal fistulas ADMIRE CD trial to enroll over 200 patients in 46 centers across 8 countries Leuven (BELGIUM) - July 10, 2012 - TiGenix (NYSE Euronext: TIG) announced today the enrolment of the first patients in the ADMIRE-CD trial, its pivotal Phase III clinical trial with Cx601 in perianal fistulas in Crohn`s disease patients at Hospital Clnic, Barcelona, Spain. Cx601 is an adipose derived allogeneic stem cell therapy. ADMIRE-CD is a multicenter, randomized, double-blind, placebo-controlled Phase III trial of Cx601 in approximately 200 Crohn`s disease patients suffering from complex perianal fistulas. The main objectives of the study are to demonstrate safety and superior efficacy over placebo in perianal fistulas in Crohn`s disease patients after failure with their previous treatment, in most cases biologicals, and to confirm the strong safety and efficacy results from the Phase II trial completed in 2011. To date, the company has already received approvals from Ethical Committees or Regulatory Agencies in 7 out of 8 countries, which should allow the company to accelerate patient enrolment in the study. Dr. Jose Luis Bravo, VP Global Medical Affairs & … Continue reading →

Posted in Mesenchymal Stem Cells | Comments Off on TiGenix : enrolment first patients in pivotal Phase III trial with lead product Cx601

TiGenix Enrolls First Patients in Pivotal Phase III Trial With Lead Product Cx601 in Perianal Fistulas

Posted: Published on July 10th, 2012

LEUVEN, BELGIUM--(Marketwire -07/10/12)- TiGenix (EURONEXT:TIG) announced today the enrolment of the first patients in the ADMIRE-CD trial, its pivotal Phase III clinical trial with Cx601 in perianal fistulas in Crohn's disease patients at Hospital Clnic, Barcelona, Spain. Cx601 is an adipose derived allogeneic stem cell therapy. ADMIRE-CD is a multicenter, randomized, double-blind, placebo-controlled Phase III trial of Cx601 in approximately 200 Crohn's disease patients suffering from complex perianal fistulas. The main objectives of the study are to demonstrate safety and superior efficacy over placebo in perianal fistulas in Crohn's disease patients after failure with their previous treatment, in most cases biologicals, and to confirm the strong safety and efficacy results from the Phase II trial completed in 2011. To date, the company has already received approvals from Ethical Committees or Regulatory Agencies in 7 out of 8 countries, which should allow the company to accelerate patient enrolment in the study. Dr. Jose Luis Bravo, VP Global Medical Affairs & Clinical Development of TiGenix, said: "We are delighted to enrol the first patient in the ADMIRE-CD trial. Hospital Clnic has pioneered the use of stem cell therapies to treat Crohn's disease, and we believe that Cx601 may prove to be a … Continue reading →

Posted in Mesenchymal Stem Cells | Comments Off on TiGenix Enrolls First Patients in Pivotal Phase III Trial With Lead Product Cx601 in Perianal Fistulas

BioView and ScreenCell Announce Worldwide Commercial Collaboration Agreement for Circulating Tumor Cell (CTC) Technology

Posted: Published on July 10th, 2012

REHOVOT, Israel and PARIS, July 9, 2012 /PRNewswire/ -- BioView Ltd. (BIOV.TA) and ScreenCell, a privately-held company, today jointly announced the signing of a commercial collaboration agreement for Bioview's Automated Cell Imaging Systems for imaging of CTC's isolated with ScreenCell's Cyto Kit . Dr. Alan Schwebel, President and CEO of BioView, views this agreement as a unique combination of two innovative technologies, one designed by ScreenCell to isolate rare cells of potentially significant prognostic and predictive value in cancer, and another, BioView's scanning platform, which provides automated imaging and analysis solutions for rare cell and circulating tumor cell detection. "BioView's unique automated imaging and analysis solutions for the detection and of rare cells greatly enhance research and clinical laboratory productivity and assay development process. We are proud to be ScreenCell's global partner and look forward to expanding our relationship." Bioview's Imaging Systems are designed to accommodate both the need for CTC enumeration and retrieval of cellular and marker characteristics of captured cells. Utilizing field-proven algorithms developed and perfected in collaboration with leading cancer research centers worldwide, BioView's scanning platform is the ideal solution for both clinical and research laboratories wishing to enhance their productivity and assay development processes. ScreenCell offers … Continue reading →

Posted in Mesenchymal Stem Cells | Comments Off on BioView and ScreenCell Announce Worldwide Commercial Collaboration Agreement for Circulating Tumor Cell (CTC) Technology

New Type of Stem Cell Preparation Could Bring Pain Relief to Diabetics

Posted: Published on July 10th, 2012

Durham, NC (PRWEB) July 09, 2012 A new study released today in STEM CELLS Translational Medicine shows the potential of a new approach in preparing stem cells that provide relief to people suffering from a common, yet painful diabetes complication. About 70 percent of diabetics have neuropathy, or nerve damage, resulting from the disease, according to the National Institutes of Health. The most common type is peripheral neuropathy (DPN), which causes pain or loss of feeling in the toes, feet, legs, hands and arms. Up to a quarter of DPN sufferers endure an extremely painful version (pDPN) in which even a tiny amount of external pressure can be excruciating. While there are many contributors to DPN, inflammation is considered a major culprit. Treatments are generally restricted to controlling the diabetes itself and to alleviating pain with topical ointments such as capsaicin cream or with oral medications including antidepressants and anticonvulsants. However, none of these therapies directly targets the inflammation, most have negative side effects and less than 30 percent of patients experience adequate pain relief. Clearly, new therapies are needed, said Dr. Ruth Waterman of the Ochsner Clinic Foundation in New Orleans. Dr. Waterman collaborated with Dr. Aline Betancourt from … Continue reading →

Posted in Mesenchymal Stem Cells | Comments Off on New Type of Stem Cell Preparation Could Bring Pain Relief to Diabetics

Drug may avert chemo side effects

Posted: Published on July 9th, 2012

The new drug will be tested on patients with lymphoma and leukaemia. Photo: Phil Carrick MELBOURNE scientists believe they have found a new treatment for blood cancers that will spare patients the unpleasant side effects of chemotherapy. The new drug, which has shown promising results in mice, will be tested on patients with lymphoma and leukaemia at Peter MacCallum Cancer Centre later this year. In a career-defining breakthrough, Associate Professor Ross Hannan from the hospital found a weakness in cancer cells that could be targeted to kill them while sparing healthy cells. The weakness is a process called ribosome biogenesis, which produces proteins essential for the growth and survival of all cells. Advertisement ''We've demonstrated that cancer cells are far more dependent on their ability to make ribosomes than normal cells, and therefore, much more vulnerable if these ''protein factories" come under attack,'' he said of the research published yesterday in the journal Cancer Cell. After working with an American pharmaceutical company, Professor Hannam and his colleagues found a drug that could target this process, killing the cancer cells in mice with little impact on healthy cells. Professor Grant McArthur, co-head of the Cancer Therapeutics Program at Peter MacCallum Cancer … Continue reading →

Posted in Drug Side Effects | Comments Off on Drug may avert chemo side effects

Australians to run trials for new blood cancer drug

Posted: Published on July 9th, 2012

AUSTRALIAN scientists believe they have found a treatment for blood cancers that will spare patients the unpleasant side-effects of chemotherapy. The new drug, which has shown promising results in mice, will be tested on patients with lymphoma and leukaemia at Peter MacCallum Cancer Centre in Melbourne this year. An Associate Professor, Ross Hannan, from the hospital, found a weakness in cancer cells that could be targeted to kill them while sparing healthy cells. The weakness is a process called ribosome biogenesis, which produces proteins essential for the growth and survival of all cells. ''We've demonstrated that cancer cells are far more dependent on their ability to make ribosomes than normal cells, and therefore, much more vulnerable if these 'protein factories' come under attack,'' he said of the research, published today in the journal Cancer Cell. Advertisement After working with an American pharmaceutical company, Associate Professor Hannan and his colleagues found a drug that could target this process, killing the cancer cells in mice with little effect on healthy cells. A professor and co-head of the cancer therapeutics program at Peter MacCallum Cancer Centre, Grant McArthur, said: ''This will hopefully lead to the eradication of lymphoma and leukaemia cells in patients.'' … Continue reading →

Posted in Drug Side Effects | Comments Off on Australians to run trials for new blood cancer drug

Pine Grove's Newest Treatment Center Changes the Legacy of Older Addicts

Posted: Published on July 9th, 2012

HATTIESBURG, Miss., July 9, 2012 (GLOBE NEWSWIRE) -- Pine Grove Behavioral Health and Addiction Services announces the opening of its newest addiction treatment program for patients 60 and older, Legacy. With an estimated three million older Americans struggling with addiction, the newly renovated wing is one of the few treatment facilities in the world designed specifically for older adults with alcohol, prescription medication and illicit drug dependency. Debbie Sanford, chief officer of behavioral health services at Pine Grove, says "We have seen a growing number of older patients and realize they need a program that understands and addresses the generational as well as physical differences that often make it difficult for them to feel comfortable in traditional treatment programs." Sanford and her team enlisted the country's top expert in aging and addiction, Carol Colleran, to help with the development of the Legacy program. Colleran, a renowned educator and advocate for Boomer and older adult recovery, has spent the past 25 years developing and operating specialized addiction treatment programs for the older adult. She has participated in policy development, education and special studies for several international, national and government organizations, including the U.N., Columbia University and the Substance Abuse and Mental … Continue reading →

Posted in Drug Dependency | Comments Off on Pine Grove's Newest Treatment Center Changes the Legacy of Older Addicts

Bath salts Q and A: The evolution of a synthetic drug in the Syracuse area

Posted: Published on July 9th, 2012

Syracuse, NY -- Bath salts is an elusive drug. Its not the Epsom salts available at a bath and body store. Its not a single type of drug. And these days, it may not even be called bath salts. Here are some frequently asked questions about bath salts: What Syracuse can learn from Louisiana's "bath salts" epidemic What is it? Bath salts originally described a synthetic drug sold in crystals that mimicked the effects of amphetamines, also known as speed. The drug was first reported in Europe, including Ireland, in early 2010, according to news accounts. Since then, the drug has branched out to substances beyond Mephedrone and MDPV, the two original drugs. In slang, it now covers any synthetic drug that gives the user a euphoric high. But the term has become so well known to law enforcement that other slang terms are used: plant fertilizer, glass cleaner or research chemicals. Why is it so hard to stop? The major difference between synthetic drugs and their predecessors is that synthetic drugs can be tweaked to avoid detection and the law. Chemical test kits do not test for all drugs; law enforcement must know what drug to test for. So … Continue reading →

Posted in Drug Dependency | Comments Off on Bath salts Q and A: The evolution of a synthetic drug in the Syracuse area

Page 6,693«..1020..6,6926,6936,6946,695..6,7006,710..»